

Datasheet: AHP1073

Description:	GOAT ANTI HUMAN BID (C-TERMINAL)
Specificity:	BID (C-TERMINAL)
Format:	Purified
Product Type:	Polyclonal Antibody
Isotype:	Polyclonal IgG
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry				
Immunohistology - Frozen				
Immunohistology - Paraffin				
ELISA	•			1/8000
Immunoprecipitation				
Western Blotting	•			0.1 - 0.3ug/ml
Functional Assays			•	

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Human
Product Form	Purified IgG - liquid

Antiserum Preparation Antisera to BID (CT) were raised by repeated immunisations of goat with highly purified antigen. Purified IgG prepared affinity chromatography.

Buffer Solution	TRIS buffered saline
Preservative Stabilisers	0.02% Sodium Azide (NaN ₃) 0.5% Bovine Serum Albumin
Approx. Protein Concentrations	IgG concentration 0.5mg/ml

agonist that heterodimerizes with other members of the Bcl-2 family of cell death regulators; including the agonist BAX or antagonist BCL2. BID contains a BH3 domain, required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. Protease-cleaved BID translocates to mitochondria where it results in cytochrome c release, leading to caspase activation and cell death. This
Entrez Gene: 637 BID Related reagents AB_808344 Goat anti Human BID antibody detects an epitope within the C-terminus of BID, a death agonist that heterodimerizes with other members of the Bcl-2 family of cell death regulators; including the agonist BAX or antagonist BCL2. BID contains a BH3 domain, required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. Protease-cleaved BID translocates to mitochondria where it results in cytochrome c release, leading to caspase activation and cell death. This constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the
Entrez Gene: 637 BID Related reagents AB_808344 Goat anti Human BID antibody detects an epitope within the C-terminus of BID, a death agonist that heterodimerizes with other members of the Bcl-2 family of cell death regulators; including the agonist BAX or antagonist BCL2. BID contains a BH3 domain, required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. Protease-cleaved BID translocates to mitochondria where it results in cytochrome c release, leading to caspase activation and cell death. This constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the
Entrez Gene: 637 BID Related reagents AB_808344 Goat anti Human BID antibody detects an epitope within the C-terminus of BID, a death agonist that heterodimerizes with other members of the Bcl-2 family of cell death regulators; including the agonist BAX or antagonist BCL2. BID contains a BH3 domain, required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. Protease-cleaved BID translocates to mitochondria where it results in cytochrome c release, leading to caspase activation and cell death. This constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the
AB_808344 Goat anti Human BID antibody detects an epitope within the C-terminus of BID, a death agonist that heterodimerizes with other members of the Bcl-2 family of cell death regulators; including the agonist BAX or antagonist BCL2. BID contains a BH3 domain, required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. Protease-cleaved BID translocates to mitochondria where it results in cytochrome c release, leading to caspase activation and cell death. This constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the
Goat anti Human BID antibody detects an epitope within the C-terminus of BID, a death agonist that heterodimerizes with other members of the Bcl-2 family of cell death regulators; including the agonist BAX or antagonist BCL2. BID contains a BH3 domain, required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. Protease-cleaved BID translocates to mitochondria where it results in cytochrome c release, leading to caspase activation and cell death. This constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the
Goat anti Human BID antibody detects an epitope within the C-terminus of BID, a death agonist that heterodimerizes with other members of the Bcl-2 family of cell death regulators; including the agonist BAX or antagonist BCL2. BID contains a BH3 domain, required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. Protease-cleaved BID translocates to mitochondria where it results in cytochrome c release, leading to caspase activation and cell death. This constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the
regulators; including the agonist BAX or antagonist BCL2. BID contains a BH3 domain, required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. Protease-cleaved BID translocates to mitochondria where it results in cytochrome c release, leading to caspase activation and cell death. This constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the
regulators; including the agonist BAX or antagonist BCL2. BID contains a BH3 domain, required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. Protease-cleaved BID translocates to mitochondria where it results in cytochrome c release, leading to caspase activation and cell death. This constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the
BID contains a BH3 domain, required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. Protease-cleaved BID translocates to mitochondria where it results in cytochrome c release, leading to caspase activation and cell death. This constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the
for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. Protease-cleaved BID translocates to mitochondria where it results in cytochrome c release, leading to caspase activation and cell death. This constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the
Granzyme B and cathepsins. Protease-cleaved BID translocates to mitochondria where it results in cytochrome c release, leading to caspase activation and cell death. This constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the
results in cytochrome c release, leading to caspase activation and cell death. This constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the
constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the
death stimuli.
BID has been shown to promote cell cycle progression into S phase, whilst BID could be
also involved in the maintenance of genomic stability by engaging at mitosis checkpoint.
Deletion of BID inhibits carcinogenesis in the liver, and promotes tumorigenesis in the
myeloid cells.
AHP1073 detects bands of approximately 26kDa and 24kDa in A431 cell lysates.
1. Yin, X.M. (2006) Bid, a BH3-only multi-functional molecule, is at the cross road of life
and death. <u>Gene. 369: 7-19.</u>
This product is shipped at ambient temperature. It is recommended to aliquot and store at
-20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for
short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in
frost-free freezers is not recommended.
12 months from date of despatch
Material Safety Datasheet documentation #10058 available at:
https://www.bio-rad-antibodies.com/SDS/AHP1073
10058
For research purposes only
6 I I I I

Related Products

Recommended Secondary Antibodies

Rabbit Anti Goat IgG (Fc) (STAR122...) FITC, HRP

 North & South
 Tel: +1 800 265 7376
 Worldwide
 Tel: +44 (0)1865 852 700
 Europe
 Tel: +49 (0) 89 8090 95 21

 America
 Fax: +1 919 878 3751
 Fax: +44 (0)1865 852 739
 Fax: +49 (0) 89 8090 95 50

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M420592:230706'

Printed on 12 Aug 2023

© 2023 Bio-Rad Laboratories Inc | Legal | Imprint